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MortalityAbstract Background: Despite high contagiousness and rapid spread, severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) has led to heterogeneous outcomes across
affected nations. Within Europe (EU), the United Kingdom (UK) is the most severely affected
country, with a death toll in excess of 100,000 as of January 2021. We aimed to compare the
national impact of coronavirus disease 2019 (COVID-19) on the risk of death in UK patients
with cancer versus those in continental EU.
Methods: We performed a retrospective analysis of the OnCovid study database, a European
registry of patients with cancer consecutively diagnosed with COVID-19 in 27 centres from
27th February to 10th September 2020. We analysed case fatality rates and risk of death at
30 days and 6 months stratified by region of origin (UK versus EU). We compared patient
characteristics at baseline including oncological and COVID-19especific therapy across UK
D.J. Pinato et al. / European Journal of Cancer 150 (2021) 190e202192and EU cohorts and evaluated the association of these factors with the risk of adverse out-
comes in multivariable Cox regression models.
Findings: Compared with EU (n Z 924), UK patients (n Z 468) were characterised by higher
case fatality rates (40.38% versus 26.5%, p < 0.0001) and higher risk of death at 30 days (haz-
ard ratio [HR], 1.64 [95% confidence interval {CI}, 1.36e1.99]) and 6 months after COVID-19
diagnosis (47.64% versus 33.33%; p < 0.0001; HR, 1.59 [95% CI, 1.33e1.88]). UK patients
were more often men, were of older age and have more comorbidities than EU counterparts
(p < 0.01). Receipt of anticancer therapy was lower in UK than in EU patients (p < 0.001).
Despite equal proportions of complicated COVID-19, rates of intensive care admission and
use of mechanical ventilation, UK patients with cancer were less likely to receive anti
eCOVID-19 therapies including corticosteroids, antivirals and interleukin-6 antagonists
(p < 0.0001). Multivariable analyses adjusted for imbalanced prognostic factors confirmed
the UK cohort to be characterised by worse risk of death at 30 days and 6 months, indepen-
dent of the patient’s age, gender, tumour stage and status; number of comorbidities; COVID-
19 severity and receipt of anticancer and antieCOVID-19 therapy. Rates of permanent cessa-
tion of anticancer therapy after COVID-19 were similar in the UK and EU cohorts.
Interpretation: UK patients with cancer have been more severely impacted by the unfolding of
the COVID-19 pandemic despite societal risk mitigation factors and rapid deferral of anti-
cancer therapy. The increased frailty of UK patients with cancer highlights high-risk groups
that should be prioritised for antieSARS-CoV-2 vaccination. Continued evaluation of
long-term outcomes is warranted.
ª 2021 Elsevier Ltd. All rights reserved.1. Introduction
Coronavirus disease 2019 (COVID-19) has, since its
emergence in late 2019 [1], claimed the life of nearly 2
million people worldwide as of January 2021. The
response of healthcare services to the escalating threat
posed by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) has led to significant changes in the
practice of medicine including reorganisation and rede-
ployment of the workforce, modification to emergency
and elective services and expansion of community and
in-hospital SARS-CoV-2 testing to facilitate early
recognition of the disease and reduce risk of mortality in
patients and healthcare workers.
In over a year of rapidly accumulating observational
evidence, it is now clear that COVID-19 dispropor-
tionally affects the elderly and those with comorbidities
[2e5]. Patients with cancer are inherently susceptible to
severe SARS-CoV-2, and determinants of mortality
such as age, comorbid burden and presence of active
malignancy have been reproducibly documented as
drivers of an adverse disease course across studies
[6e10].
Despite some evidence regarding the negative role of
previous chemotherapy [11,12], anticancer therapy does
not appear to worsen the prognosis from COVID-19.
However, the immunosuppressive nature of most sys-
temic anticancer therapies (SACTs), the requirement for
regular hospital attendance and the risk of morbidity
and hospitalisation from treatment-related adverse
events have induced a more cautious delivery ofoncological therapies in an attempt to prevent harm and
avoid SARS-CoV-2 exposure.
Despite national lockdowns, social distancing mea-
sures, broad-reaching precautionary attempts and early
dissemination of clinical practice guidelines, the United
Kingdom (UK) has registered the highest number of
SARS-CoV-2erelated deaths in Europe (EU), with a
death toll in excess of 100,000 patients as of January
2021 [13].
It is unknown whether the higher mortality observed
in the general UK population translates into worse
outcomes from COVID-19einfected patients with can-
cer. Previous results from the OnCovid study have
revealed a higher case fatality rate in the UK (44.4%)
than in Italy (33.2%) and Spain (29.6%) [6]. Under-
standing whether there is regional variation in the nat-
ural course of COVID-19 is of utmost importance in the
context of a still-unresolved healthcare crisis. Such effort
not only helps portraying the healthcare system response
to COVID-19 but also can aid characterisation of
geographical heterogeneity in the clinical characteristics
underlying the vulnerability of patients with cancer to
SARS-CoV-2 infection.
In addition to regional differences in case fatality
rates from COVID-19, it is important to understand
whether deferral and discontinuation of SACT recom-
mended at the onset of the pandemic [14] might have
impacted the overall survival (OS) of patients with
cancer in the UK, a population that is already charac-
terised by poorer 5-year survival outcomes in a number
of solid tumours [15].
Missing follow-up information
144 patients
Data lock 1st November 2020
1559 patients entered 
STUDY POPOULATION: 1392 PATIENTS
(Diagnosed from the 27th of February and the 10th of September 2020)
From 6 UK centers
468 (29.3%)
From 21 EU centers
924 (66.4%)
Missing clinical outcome information
23 patients
Outcome analysis
Fig. 1. Study diagram. UK, United Kingdom; EU, Europe.
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therapy, which is known to affect oncological out-
comes in cancer [16e18], in March 2020, the UK
National Health Service identified 6 priority levels
for SACT based on treatment intent and expected
efficacy so that treatment can proceed for those in
whom benefits clearly outweigh risks [19].
In this ad hoc analysis of the OnCovid registry,
we aimed to compare and contrast the risk of death
after diagnosis of COVID-19 in patients with
cancer diagnosed in the UK versus those diagnosed
in continental EU.
2. Study design and outcomes
OnCovid (NCT04393974) is an active European regis-
try study that has collected, since the beginning of the
pandemic, consecutive patients fulfilling the following
inclusion criteria: (1) age 18 years, (2) diagnosis of
SARS-CoV-2 infection confirmed by Reverse tran-
scription polymerase chain reaction (RT-PCR) of a
nasopharyngeal swab [20] and (3) history of solid or
haematologic malignancy, at any time during the
patient’s past medical history, either active or in
remission at the time of COVID-19 diagnosis. Patients
with a history of non-invasive/premalignant lesions or
with low malignant potential (i.e. basal cell carcinoma
of the skin, non-invasive carcinoma in situ of the
cervix and ductal carcinoma in situ) were excluded. Forhaematologic malignancies, only patients with a history
of oncologic diseases with defined malignant behaviour
(lymphoma, leukaemia and multiple myeloma) were
included.
As a primary end-point of our study, we elected the
all-cause 30-day risk of death, a measure that mirrors
end-points used in clinical trials of COVID-19 thera-
peutics [21]. In view of the extended length of follow-up
of our cohort compared with earlier studies reporting
case fatality rates censored at 14 days of observation
[6e9,22,23], we reported, as an additional study end-
point, all-cause risk of death at 6 months after COVID-
19 diagnosis. The choice of this additional end-point
allowed us to preliminarily investigate determinants of
longer-term prognosis in COVID-19 survivors [24e26].
In comparing outcomes from UK and EU pa-
tients, we evaluated the distribution of baseline
characteristics already known to be major de-
terminants of mortality [6e8,22,23]. These included
gender, age, number of comorbidities, smoking his-
tory, tumour type (clustered as breast, gastrointes-
tinal, gynaecological/genitourinary, haematological,
thoracic and others) [7e9,27], tumour stage (defined
as advanced versus non-advanced as per disease-
specific criteria), tumour status (presence of active
versus non-measurable disease), receipt of anticancer
or antieCOVID-19 therapy and occurrence of
complicated COVID-19 as described before [6]. The
role of each determinant of mortality was explored
D.J. Pinato et al. / European Journal of Cancer 150 (2021) 190e202194across the two cohorts using univariable analysis.
Accounting for their unbalanced distribution across
cohorts, a fixed multivariable regression analysis
model was adopted to verify their independent
prognostic role.
The differential distribution across UK and EU
patients of other characteristics of interest including
hospitalisation and intensive care unit (ICU)Table 1
Patient characteristics of the cohorts of interest.







Male 451 (48.86) 287 (61.72) <0.0001
Female 472 (51.14) 1778 (38.28)
Missing 4
Age
<65 years 382 (41.75) 151 (32.26) 0.0006
65 years 533 (58.25) 317 (67.74)
Missing 9
Number of comorbidities
0e1 420 (45.45) 175 (37.39) 0.0041
2 504 (54.55) 293 (62.61)
Missing 0
Smoking history
Never-smokers 407 (44.97) 192 (41.29) 0.8355
Former/current smokers 383 (42.32) 176 (37.85)
Missing 234
Cancer site
Breast 219 (23.70) 58 (12.39) <0.0001
Gastrointestinal 167 (18.07) 92 (19.66)
Gynaecological/genitourinary 132 (14.29) 146 (31.20)
Haematological 172 (18.61) 53 (11.32)
Lung 118 (12.77) 58 (12.64)
Other 116 (12.55) 61 (13.03)
Missing 0
Tumour stage
Local/locoregional 390 (42.21) 294 (62.82) <0.0001





299 (32.97) 150 (32.97) 0.9996




No 371 (40.55) 278 (61.64) <0.0001
Yes 544 (59.55) 173 (38.36)
Missing 26
COVID-19 therapy (any)
No 224 (25.31) 163 (39.47) <0.0001
Yes 661 (74.69) 250 (60.53)
Missing 94
Complicated COVID-19
No 367 (39.72) 179 (8.25) 0.5955
Yes 557 (60.28) 289 (61.75)
Missing 0
COVID-19, coronavirus disease 2019; EU, Europe; UK, United
Kingdom.admission rates, need for supplemental oxygen ther-
apy and assisted ventilation, emergence of COVID-
19erelated complications and receipt of COVID-
19especific therapy was also reported as described
previously [6,23]. In addition, we reported rates of
permanent discontinuation of anticancer therapy
among those patients who were listed as receiving
anticancer therapy at COVID-19 diagnosis, including
only patients alive after 30 days since COVID-19
diagnosis.
3. Study procedures
OnCovid was granted central approval by the UK
Health Research Authority (20/HRA/1608) and by the
corresponding research ethics committees at each
participating institution outside the UK. Core study
data were collated from electronic medical records
into a case report form designed using Research
Electronic Data Capture software (REDCap; Van-
derbilt University, Nashville, TN, United States of
America [USA]). Multisite access and data curation
was coordinated by the Medical Statistics Unit in
Novara, Italy. A list of participating centres is pro-
vided in Supplementary Table 1. Six institutions were
from the UK, and 21 institutions were from conti-
nental EU. The data cut-off for the present analysis
was 1st November 2020.
4. Statistical analysis
Key baseline characteristics were summarised as cate-
gorical variables and reported as counts and percent-
ages. Associations between categorical variables were
tested using the Pearson c2 test. OS and all-cause 30-
day and 6-month survival curves for the two cohorts
of interest were also reported as per the Kaplan-Meier
method and compared using the log-rank test. OS was
defined as the survival interval from COVID-19 diag-
nosis to death and/or last follow-up. Univariable and
multivariable Cox proportional hazards models were
used to assess the impact of the factors and the
geographical area (the UK vs EU) on risk of death
from all causes at 30-day and 6-month landmark time
points. All the explored baseline characteristics have
been included in the multivariable model, in view of
their strong linkage with mortality within the study
population [6,23] and because of their differential dis-
tribution across the UK and EU cohorts. The results of
Cox regression analysis were presented as hazard ratios
(HRs) and the corresponding 95% confidence intervals
(95% CIs). A p-value of <0.05 was considered statis-
tically significant. Analyses were performed using SAS
software, version 9.4 (SAS Institute Inc., Cary, NC,
USA), and SPSS, version 25 (IBM Inc.).
Fig. 2. (A) Histograms illustrating the case fatality rates at 30 days and 6 months for the cohorts of interest. Kaplan-Meier survival curves.
(B) Overall survival for the entire study population: 6.3 months (95% CI: 4.4e6.3; 532 events). (C) Overall survival for the cohorts of
interest: UK cohort, 2.7 months (95% CI: 1.5e4.3; 223 events); EU cohort, 6.3 months (95% CI: 6.3e6.3; 309 events). Log-rank:
p < 0.0001. CI, confidence interval; UK, United Kingdom; EU, Europe.
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5.1. Demographic features of UK and EU patients with
cancer and COVID-19
At database lock, the registry included 1559 patients
consecutively diagnosed with COVID-19. A total of 167
patients were excluded because of missing outcome data
(n Z 23) or loss to follow-up (n Z 144). The final
population consisted of 1392 patients accrued from 27
institutions across 6 countries (UK, Italy, Spain, France,
Belgium and Germany) and diagnosed with COVID-19
between 27th February and 10th September 2020
(Fig. 1). Patient distribution across the participating
centres is provided in Supplementary Table 1.
The UK cohort included 468 patients (33.6%),
whereas the continental EU cohort included 924 patients
(66.4%). The distribution of baseline patient character-
istics across cohorts is summarised in Table 1.
The distribution of primary tumours between the two
cohorts was significantly different across cohorts
(p < 0.0001): the UK cohort had a lower proportion of
patients with breast cancer (12.39% vs 23.70%) and
haematological malignancies (11.32% vs 18.61%) and a
higher proportion of patients with gynaecological/genitourinary cancer (31.20% vs 14.29%) than the con-
tinental EU cohort.
Compared with the rest of EU, the UK cohort
included a significantly higher proportion of patients
with adverse baseline features with respect to COVID-
19erelated outcomes, including male gender (61.72% vs
48.86%, p < 0.0001), age 65 years (67.74% vs 58.25%,
p Z 0.0006) and 2 comorbidities (62.61% vs 54.5%,
p Z 0.0041). Conversely, UK patients were less likely to
have advanced-stage cancer (32.26% vs 41.13%,
p < 0.0001) and to be receiving active anticancer therapy
within 4 weeks before COVID-19 diagnosis (60.53% vs
74.69%, p < 0.0001). No difference between the cohorts
was found with respect to smoking status (former/cur-
rent smokers: 37.85% vs 42.32%, p Z 0.8355), the
presence of active malignancy (67.03% vs 67.03%,
p Z 0.9996) and rates of complicated COVID-19
(61.75% vs 60.28%, p Z 0.5955). However, UK pa-
tients were less likely to have received COVID-
19especific therapies of any kind (60.53% vs 74.69%,
p < 0.0001).
Supplementary Table 2 provides the detailed distri-
bution across the cohorts of patients’ comorbidities,
specific anticancer therapy, COVID-19 symptoms at
diagnosis, complications and provision of COVID-
Fig. 3. Kaplan-Meier survival curves. (A) Thirty-day survival for the cohorts of interest: UK cohort, not reached (189 events); EU cohort,
not reached (245 events). Log-rank: p < 0.0001. (B) Six-month survival for the cohorts of interest: UK cohort, 2.7 months (95% CI:
1.5e4.3; 223 events); EU cohort, not reached (208 events). Log-rank: p < 0.0001. CI, confidence interval; UK, United Kingdom; EU,
Europe.
D.J. Pinato et al. / European Journal of Cancer 150 (2021) 190e20219619especific therapy. It also summarises hospitalisation
and ICU admission rates across the cohorts. Although a
higher proportion of hospitalisations were reported for
the UK cohort (87.39% vs 82.47%, p Z 0.0175), there
was no significant difference regarding ICU admission
rates (14.14% vs 13.77%, p Z 0.6919), requirement for
oxygen therapy (57.91% vs 57.86%, p Z 0.9868) and
mechanical ventilation (12.29% vs 10.30%, p Z 0.8630).
However, a higher proportion of patients requiring non-
invasive ventilation were reported in the UK cohort
(71.15% vs 36.78%, p < 0.0001). Among patients who
were on anticancer therapy at the moment of COVID-19
diagnosis and were alive at 30 days (n Z 406), no sig-
nificant difference was found in the rates of permanent
cessation of anticancer therapy after COVID-19 be-
tween the UK (nZ 10 of 94, 10.6%) and the EU cohorts
(n Z 32 of 312, 10.3%, p Z 0.9152).
5.2. Clinical outcomes
The median follow-up interval for the entire population
was 2.2 months (95% CI: 2.1e7.1) and similar for the
UK (2.2 months [95% CI: 2.1e6.7]) and EU cohort (2.2
months [95% CI: 2.0e7.1]). When considering the entire
population (n Z 1392), the overall all-cause case fatality
rates at 30 days and 6 months were 31.17% (434 events)
and 38.14% (531 events), respectively. As shown in
Fig. 2A, case fatality rates were higher in UK versus EU
patients both at 30 days (40.38%, 189 events versus
26.5%, 245 events; p < 0.0001) and at 6 months (47.64%,
223 events versus 33.33%, 308 events; p < 0.0001).
At the time of censoring, the median survival time of
the overall OnCovid population was 6.3 months (95%
CI: 4.4e6.3), with 532 recorded deaths. Fig. 2B and C
illustrate the Kaplan-Meier estimation of OS for the
entire population and after stratification into UK and
EU cohorts. Univariable analyses revealed patients from
the UK cohort to have experienced a significantly higher
risk of death at 30 days (HR Z 1.64 [95% CI:
1.36e1.99]) and 6 months (HR Z 1.58 [95% CI:1.33e1.88]) than patients from the EU cohort. Fig. 3A
and B illustrate the significant difference in patients’ OS
at 30-day and 6-month landmark time points for UK
versus EU patients.
5.3. Risk factors of outcomes in UK versus EU patients
with cancer andCOVID-19
To evaluate clinical determinants of worse outcomes
in UK patients with cancer and COVID-19, we
initially performed univariable analyses to identify
the factors associated with the risk of death at 30
days and 6 months in the whole population (Table
2). Alongside a significant increase in the risk of
death at 30 days (HR Z 1.64, 95% CI: 1.36e1.99)
and 6 months (HR Z 1.58, 95% CI: 1.333e1.881)
documented for UK patients, we confirmed patients’
gender, age, number of comorbidities, smoking sta-
tus, tumour stage, status and occurrence of compli-
cated COVID-19 were to be significantly associated
with an increased risk of death at 30 days and 6
months, in line with previously published reports
[6,22,23]. Receipt of anticancer therapy at COVID-
19 diagnosis was significantly associated with
improved risk of death at both the 30-day and 6-
month landmarks, a finding that mirrors previously
published evidence from the OnCovid study [6]. With
the exception of patients with breast cancer and
those in the other malignancy subgroup, who were
characterised by a decreased risk of death at 30 days
and at 6 months compared with patients with lung
cancer, no other significant differences were found
with respect to clinical outcomes regarding primary
tumour subgroups.
To evaluate whether UK origin was independently
associated with outcomes, we designed a multivariable
Cox regression model adjusted for all the prognostic
covariates tested in univariable models. As shown in
Table 3, after adjustment for all the included covariates,
patients from the UK cohort were confirmed to have a
Table 2
Univariable analysis of factors predictive for the risk of death at 30 days and 6 months.
30 days HR (95% CI) 6 months HR (95% CI)
Alive Death Alive Death
N Z 958 (%) N Z 434 (%) N Z 861 (%) N Z 531 (%)
Area
Other EU 679 (70.88) 245 (56.45) 1 616 (71.54) 308 (58.00) 1
UK 279 (29.12) 189 (43.55) 1.64 (1.36e1.99) 245 (28.46) 223 (42.00) 1.58 (1.333e1.881)
Gender
Male 474 (49.63) 264 (60.97) 1 414 (48.25) 324 (61.13) 1
Female 481 (50.37) 169 (39.03) 0.68 (0.56e0.83) 444 (51.75) 206 (38.87) 0.68 (0.573e0.813)
Missing 4 4
Age
<65 years 438 (46.01) 95 (22.04) 1 407 (47.49) 126 (23.95) 1
65 years 514 (53.99) 336 (77.96) 2.53 (2.01e3.18) 450 (52.51) 400 (76.05) 2.39 (1.963e2.932)
Missing 9 9
Number of comorbidities
0e1 457 (47.70) 138 (31.80) 1 428 (49.71) 167 (31.45) 1
2 501 (52.30) 296 (68.20) 1.78 (1.45e2.18) 433 (50.29) 364 (68.55) 1.89 (1.574e2.272)
Missing 0 0
Smoking history
Never-smokers 431 (53.74) 168 (47.19) 1 395 (54.33) 204 (47.33) 1
Former/current smokers 371 (46.26) 188 (52.81) 1.25 (1.01e1.54) 332 (45.67) 227 (52.67) 1.24 (1.031e1.504)
Missing 234 234
Cancer site
Breast 226 (23.90) 48 (11.06) 0.35 (0.25e0.51) 216 (25.09) 61 (11.49) 0.39 (0.28e0.55)
Gastrointestinal 172 (17.95) 87 (20.05) 0.76 (0.55e1.03) 147 (17.07) 112 (21.09) 0.85 (0.64e1.1)
Gynaecological/genitourinary 184 (19.21) 94 (21.66) 0.76 (0.56e1.03) 166 (19.28) 112 (21.09) 0.80 (0.60e1.06)
Haematological 142 (14.82) 83 (19.12) 0.78 (0.57e1.07) 121 (14.05) 104 (19.59) 0.79 (0.59e1.06)
Lung 102 (10.65) 74 (17.05) 1 92 (10.69) 84 (15.82) 1
Other 129 (13.47) 48 (11.06) 0.58 (0.40e0.84) 119 (13.82) 58 (10.92) 0.59 (0.42e0.83)
Missing 0 0
Tumour stage
Local/locoregional 501 (59.71) 183 (48.67) 1 467 (61.94) 217 (47.07) 1
Advanced 338 (40.29) 193 (51.33) 1.42 (1.16e1.74) 287 (38.06) 244 (52.93) 1.58 (1.32e1.90)
Missing 177 177
Tumour status
Remission/non-measurable disease 342 (36.62) 107 (25.00) 1 332 (38.57) 117 (22.37) 1
Active malignancy 592 (63.38) 321 (75.00) 1.55 (1.24e1.93) 507 (60.43) 406 (77.63) 1.85 (1.51e2.28)
Missing 30 30
Anticancer therapy at COVID-19 diagnosis
No 419 (44.62) 230 (53.86) 1 371 (43.96) 278 (53.26) 1
Yes 520 (55.38) 197 (46.14) 0.72 (0.59e0.87) 473 (56.04) 244 (46.74) 0.73 (0.61e0.87)
Missing 26 26
COVID-19 therapy (any)
No 283 (31.20) 104 (26.60) 1 258 (31.39) 129 (27.10) 1
Yes 624 (68.80) 287 (73.40) 1.16 (0.92e1.45) 564 (68.61) 347 (72.90) 1.15 (0.94e1.41)
Missing 94 94
Complicated COVID-19
No 488 (50.94) 58 (13.36) 1 445 (51.68) 101 (19.02) 1
Yes 470 (49.06) 376 (86.64) 5.10 (3.86e6.72) 416 (48.32) 430 (80.98) 3.53 (2.84e4.38)
Missing 0 0
COVID-19, coronavirus disease 2019; EU, Europe; UK, United Kingdom; HR, hazard ratio; CI, confidence interval.
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[95% CI: 1.17e1.99]) and at 6 months (HR Z 1.41 [95%
CI: 1.10e1.80]) than patients from the rest of EU.
Multivariable analysis confirmed receipt of anticancer
therapy not to influence the risk of death at 30-
day mortality but to exert a protective effect at 6 months
(HR Z 0.72 [95% CI: 0.57e0.92]). Exposure to any
COVID-19especific therapy was found to be associated
with a decreased risk of death at 30 days (HR Z 0.72
[95% CI: 0.59e0.87]) and at 6 months (HR Z 0.73 [95%CI: 0.61e0.87]), whereas the occurrence of complicated
COVID-19 was confirmed to be associated with an
increased risk of death at both 30 days (HRZ 5.10 [95%
CI: 3.86e6.72]) and 6 months (HR Z 3.53 [95% CI:
2.84e4.38]).6. Discussion
The high proportion of asymptomatic transmission
has made SARS-CoV-2 a rapidly escalating global
Table 3
Multivariable analysis of factors predictive of the risk of death at 30





HR (95% CI) HR (95% CI)
Area
Other EU 1 1
UK 1.52 (1.17e1.99) 1.41 (1.10e1.80)
Gender
Male 1 1
Female 1.09 (0.82e1.45) 1.12 (0.86e1.45)
Age
<65 years 1 1
65 years 1.76 (1.30e2.39) 1.60 (1.23e2.10)
Number of comorbidities
0e1 1 1
2 1.34 (1.02e1.76) 1.50 (1.17e1.92)
Smoking history
Never-smokers 1 1
Current/former smokers 1.18 (0.92e1.52) 1.18 (0.93e1.48)
Cancer site
Breast 0.84 (0.51e1.37) 0.84 (0.54e1.32)
Gastrointestinal 1.08 (0.74e1.57) 1.22 (0.86e1.71)
Gynaecological/
genitourinary
0.89 (0.61e1.28) 0.94 (0.67e1.33)
Haematological 1.29 (0.82e2.04) 1.20 (0.78e1.85)
Lung 1 1
Other 0.86 (0.52e1.40) 0.92 (0.59e1.43)
Tumour stage
Local/locoregional 1 1









Yes 0.81 (0.62e1.06) 0.72 (0.57e0.92)
COVID-19 therapy (any)
No 1 1
Yes 0.63 (0.48e0.84) 0.72 (0.55e0.93)
Complicated COVID-19
No 1 1
Yes 6.99 (4.61e10.62) 4.52 (3.26e6.26)
COVID-19, coronavirus disease 2019; EU, Europe; UK, United
Kingdom; HR, hazard ratio; CI, confidence interval.
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evenly distributed across affected countries [28]. A
number of factors play a role in determining this
heterogeneity, including differences in infection con-
trol policies, healthcare systems, racial disparity and
diverse distribution of age and comorbidities.
Although a number of studies have evaluated severity
of COVID-19 in patients with cancer versus patients
without cancer [29], little effort has been dedicated to
understanding whether the mortality of patients with
cancer and COVID-19 is geographically influenced.
The UK has reported one of the highest numbers of
deaths per capita from COVID-19 in EU, and itdetained the world primate before SARS-CoV-2 in-
fections peaked in the Americas [28].
Our ad hoc analysis of the OnCovid registry confirms
that UK patients with cancer were 1.5 times more likely
to die from COVID-19 than patients enrolled from EU
countries. In line with many other studies, our analysis
confirms that exposure to anticancer therapy plays no
role in the 30-day risk of death from COVID-19
[6,9,23,30]. Interestingly, UK patients were less likely
to be receiving anticancer therapy at the moment of
COVID-19 diagnosis. This is likely to reflect, at least in
part, the rapid diffusion of the National Institute of
Clinical Excellence guidelines on SACT prioritisation
and deferral in the UK on 20th March 2020 [31].
Previously published evidence from the OnCovid
registry had shown that patients on active anticancer
therapy achieved better outcomes from COVID-19 as
they were more likely younger, of female gender, with
fewer comorbidities and with lower proportion of active
disease [6]. Consistent with this view, in this updated
analysis of the OnCovid registry data, recent exposure
to anticancer therapy was protective for the risk of
mortality at 6 months in the UK and EU cohorts, sug-
gesting the survival disadvantage seen in UK patients to
be independent from the delivery of anticancer therapy
per se and reflect different degrees of patient fitness, for
which candidacy to SACT may act as a proxy.
Interestingly, the significantly higher risk of death of
UK patients was not restricted to estimates at 30 days
after COVID-19 diagnosis but persisted in the evalua-
tion of mortality at 6 months after infection. Although
there are no high-quality data to characterise excess risk
of long-term mortality attributable to COVID-19, recent
studies have demonstrated the considerable long-term
impact of SARS-CoV-2 on respiratory function, fatigue
and psychological well-being in patients without cancer
[32,33]. We hypothesised that an imbalance in the
resumption of anticancer therapies in the UK versus EU
cohort might be contributory to the differential risk of
death. Our results, however, argue against that inter-
pretation, given the rates of permanent discontinuation
of therapy were similar across UK and EU cohorts.
Careful evaluation of baseline patient characteristics
gives important insight as to the geographical difference
in outcomes from COVID-19, highlighting a number of
vulnerabilities that are typical of patients with cancer in
the UK. In particular, the higher proportion of male,
elderly patients with higher comorbid burden highlights
a higher degree of frailty in UK patients.
The constellation of clinical features enriched in the
UK cohort has been long time characterised as adverse
prognostic traits in patients with cancer, capable of
defining a state of intrinsic vulnerability and poor return
to physiologic homoeostasis after a stressor event [34].
Recognition of these adverse prognostic factors from
the patient’s medical and oncological history should
continue to inform the basis of an individualised risk
D.J. Pinato et al. / European Journal of Cancer 150 (2021) 190e202 199assessment in planning hospital attendance, in delivery
of cancer care and in prioritising the delivery of immu-
nisation against SARS-CoV-2 in a context of scarce
vaccinal resources [35].
Baseline patient features are not the sole de-
terminants of outcomes to COVID-19, and despite the
unfavourable imbalance in prognostic factors for UK
patients, our multivariate analyses of survival were
adjusted for all the available key confounders present at
baseline and during the course of the observation
including the emergence of COVID-19 complications
and receipt of antieCOVID-19 therapy [6,7,9,22,23].
Interestingly, patients in the UK cohort were less
likely to have received specific antieCOVID-19 therapy,
a factor that emerged to be protective for 30-day and 6-
month risk of death after adjustment for COVID-19
severity.
When considering antieCOVID-19 therapies in
detail (Supplementary Table 2), it should be emphasised
that most agents listed were used off-label or on
compassionate grounds on the basis of the opinion of
the treating physician. Although some agents including
hydroxychloroquine were later on judged ineffective in
reducing mortality [36], others such as interleukin-6 in-
hibitors, corticosteroids and remdesivir were subse-
quently shown to improve some COVID-19erelated
outcomes in different stages of disease [21,37e40]. A
direct cause-effect relationship between exposure to each
agent and mortality from COVID-19 across UK and
EU cohorts cannot be inferred because of the observa-
tional, retrospective nature of our study, wherein most
patients were treated with varying combinations of
agents and in response to different levels of severity of
the disease. However, the lower level of exposure to
antieCOVID-19 therapies that have been proven
effective such as corticosteroids and tocilizumab cannot
be discounted as a potential factor influencing the worse
outcome of patients belonging to the UK cohort.
Another important aspect that should be considered
in interpreting our results is hospital capacity, one of the
determining factors for the overall COVID-19 mortality
in the UK during the first wave [28]. In our study, we
report a higher hospitalisation rate for UK patients than
for EU patients, despite equal proportion of compli-
cated COVID-19 and no differences with regard to the
intensive care admission rates and mechanical ventila-
tion. Although a registry study such as OnCovid cannot
claim to be fully illustrative of the countrywide hospital
capacity, the lack of difference in key measures of
severity and treatment escalation aids us in addressing
hospital capacity and escalation of treatment beyond
ward-based care as important confounders in our esti-
mates of mortality. To this end, we believe the higher
hospitalisation rate of UK patients to be an imperfectindicator of capacity or severity of COVID-19, being
more likely to reflect the scarcity of community testing
observed at the early beginning of the pandemic in the
UK, when SARS-CoV-2 PCR testing capacity was
limited to hospitalised patients and to those with more
severe forms of COVID-19.
Although many studies have described outcomes
from SARS-CoV-2einfected patients with cancer in the
UK [8,22], this is the first study to perform a compar-
ative assessment of outcomes taking advantage of a
large cohort of European patients. Our study is largely
an account of the first wave of the pandemic and pre-
dates the widespread diffusion of the variant of concern
B.1.1.7, for which increased lethality has been postu-
lated [41], but not definitively proven. With increased
physician experience, resilience of healthcare services
and widespread use of active antieCOVID-19 therapies,
infections diagnosed in the so-called ‘second wave’
might be characterised by improved outcomes: a hy-
pothesis that we aim to test when clinical data from our
registry are fully mature. Similarly, although our study
relies on significantly longer follow-up time than that in
earlier reports, more mature survival data will allow us
to provide further insight into the topic of long-term
outcomes from COVID-19.
Despite attempting to control for key clinicopatho-
logical factors, our analyses might still be affected by
unmeasured bias. For instance, we lack data on quan-
titative estimation of the SARS-CoV-2 viral load, a
parameter associated with disease severity and mortality
from COVID-19 [42] and that might have given us
insight into severity of community exposure or the un-
derlying immune dysfunction in our study participants
[43e45].
Notwithstanding the acknowledged limitations, this
study provides a comprehensive, comparative assess-
ment of the impact of the SARS-CoV-2 pandemic in
UK patients with cancer, a population already charac-
terised by intrinsically poorer survival outcomes from
cancer compared with many other industrialised coun-
tries [15]. We highlight key areas of vulnerability to
COVID-19 in UK patients with cancer, in particular
higher comorbid burden and age, which, in a healthcare
system characterised by the highest overall mortality
from COVID-19 in EU, calls for the rapid imple-
mentation of protective strategies against SARS-CoV-2
in this exquisitely vulnerable patient cohort.
Rapid and widespread vaccination of patients with
cancer should be advocated as a priority in UK patients
with cancer. Second, clinical use of antieCOVID-19
therapies with proven benefit against SARS-CoV-2
should be facilitated in UK patients with cancer, a
population that is under-represented in clinical trials of
vaccines and therapeutics against SARS-CoV-2 [46].
D.J. Pinato et al. / European Journal of Cancer 150 (2021) 190e202200Although the UK is at the forefront of drug develop-
ment in COVID-19 [47], concerted efforts should
continue to be aimed at maintaining the ever-so-delicate
balance between protection from harm due to the
pandemic and preservation of oncological outcomes in
patients at risk of cancer relapse or progression.
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